[ 123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

Abstract

Disclaimer/Complaints regulationsIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. Summary. We investigated the applicability [ 123 I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD.Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [ In order to demonstrate a significant effect (p Ͻ 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123 I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123 I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.

Neuroimaging in Parkinson’s disease

“…[47][48][49] In early PD patients treated with L-dopa putamen, 18 F-dopa uptake has been reported to decline annually by around 10% of baseline (5% of the normal mean), whereas caudate uptake falls at a slower rate. Similar rates of loss of putamen dopamine transporter binding have been reported with 18 F-CFT PET 50 and with 123 I-␤-CIT, 51 123 I-FP-CIT, 52 and 123 I-IPT SPECT. 53 …”

Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images

“…This neurodegenerative process is associated with a loss of striatal dopamine transporters (DATs) as shown by postmortem studies (1,2). Therefore, in vivo measurement of DAT density with PET or SPECT is an early marker of the dopaminergic cell loss in subjects with parkinsonian symptoms or in asymptomatic carriers of genetic mutations causing PD (3)(4)(5)(6)(7). In clinical routine, DAT SPECT images are often analyzed visually.…”

Imaging in Parkinson's Disease

“…[ 123 I]-FP-CIT SPECT showed consistent results with an annual decrease in striatal binding ratios of 8% (Winogrodzka et al, 2001). Also, [ 123 I]-IPT SPECT and [ 99 Tcm]-TRODAT-1 uptake in the striatum showed a progressive decline with the progression of the disease (Tatsch et al, 1997;Weng et al, 2004), and lower striatal uptake correlated with increased motor symptoms severity as measured by the Unified PD Rating Scale part III (UPDRS-III) and Hoehn and Yahr (H&Y) stage (Tatsch et al, 1997;Weng et al, 2004).…”

“…Lower [ 123 I]-FP-CIT binding in the putamen was found in PD patients compared to patients with ET or drug-induced parkinsonism (Cuberas-Borrós et al, 2011). Dopaminergic degeneration of DAT is an age-related process; however, it is much faster in PD than in physiological aging (Winogrodzka et al, 2001). Pathology and clinical symptoms of PD progress gradually starting as unilateral and progressively affecting both sides (Larsen et al, 2008).…”

“…DAT-SPECT has been proven to be an objective tool for monitoring PD progression. (Marek et al, 2001;Tatsch et al, 1997;Weng et al, 2004;Winogrodzka et al, 2001Winogrodzka et al, , 2003. [ 123 I]-β-CIT SPECT have been used in a group of 50 early-stage PD patients showing an average decrease of 8% in the whole striatum (8% in the putamen and 4% in the caudate) at 12-month follow-up (Winogrodzka et al, 2003).…”